News
RGEN
166.70
+0.62%
1.04
Danaher Q1: The Worst Time Has Already Passed
Danaher Corporation stock has surged by 16% since our "Strong Buy" rating in June 2023. The bioprocessing industry is facing near-term challenges, but long-term growth prospects remain strong. Danaher's organic revenue declined by 4% in Q1 FY24, driven by weak growth in biotechnology and life sciences. The company's strong leadership and role in the biotech industry inspire confidence.
Seeking Alpha · 16h ago
Artisan Mid Cap Fund Q1 2024 Commentary
Seeking Alpha · 2d ago
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Shares of HealthStream, Inc. Rose sharply on Tuesday following upbeat quarterly results. The Nasdaq Composite gained over 200 points in Tuesday's session. Hibbett shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion.
Benzinga · 2d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 3d ago
Danaher gains as Q1 results exceed expectations
Danaher (DHR) shares added ~9% premarket Tuesday after the company topped Street forecasts with its Q1 2024 financials. The life sciences toolmaker reported $5.8B in revenue for the quarter with a 3% YoY decline in sales.
Seeking Alpha · 3d ago
Weekly Report: what happened at RGEN last week (0415-0419)?
Weekly Report · 4d ago
Positive Report for Repligen (RGEN) from Craig-Hallum
TipRanks · 04/19 13:15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Repligen Corporation (NASDAQ:RGEN) does carry debt. At the end of December 2023, Repligen had US$579.6m of debt. Its balance sheet shows it holds US$751.3m in cash. The company has more cash than debt and a decent-looking balance sheet. Repligen has two warning signs we think you should be aware of. It's worth looking at Repligen's free cash flow to see if the debt is a concern.
Simply Wall St · 04/15 12:06
Weekly Report: what happened at RGEN last week (0408-0412)?
Weekly Report · 04/15 09:10
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
908 Devices, Inc. Is a company focused on mass spectrometry and bioprocessing 4.0. The company has three main platforms for growth in the forensic industry. Life science tools are essential for the growth of the healthcare industry. 908 Devices is a rare early-stage investment opportunity in the life science tools industry.
Seeking Alpha · 04/10 16:49
RBC Capital Remains a Buy on Repligen (RGEN)
Repligen Corp. Provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company’s shares closed yesterday at $174.05. The analyst consensus on Repligen is a Strong Buy with an average price target of $216.00.
TipRanks · 04/09 01:45
Weekly Report: what happened at RGEN last week (0401-0405)?
Weekly Report · 04/08 09:10
REPLIGEN CORP <RGEN.O>: RBC CUTS TARGET PRICE TO $221 FROM $225
Reuters · 04/08 06:30
Relative Strength Alert For Repligen
NASDAQ · 04/02 16:18
Weekly Report: what happened at RGEN last week (0325-0329)?
Weekly Report · 04/01 09:10
Should Weakness in Repligen Corporation's (NASDAQ:RGEN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Repligen (NASDAQ:RGEN) has a return on equity of 2.1%. The company grew its net income at a rate of 34% in the last five years. Repligen's ROE is lower than the average for its industry. The company has a good growth rate, but is not considered a good indicator of future growth. It has a better ROE than the industry average of 12%. Repligen is currently down 7.9% for the week.
Simply Wall St · 03/29 14:48
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Shares of Aehr Test System tumbled 18.1% to $12.01 on Monday. The company reported preliminary third-quarter and FY24 results below estimates. The Dow Jones index fell around 100 points in today's session. Vimeo, Canopy Growth Corporation and United Airlines also recorded losses.
Benzinga · 03/25 14:32
Weekly Report: what happened at RGEN last week (0318-0322)?
Weekly Report · 03/25 09:10
Repligen: Current report
Press release · 03/19 12:52
Repligen Corp Announces Board Appointment and Compensation Plan
TipRanks · 03/19 11:52
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.